{"title": "Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza", "doi": "10.1101/2020.03.13.991307", "citation_id": "2020.03.13.991307v1", "date": "2020-03-14", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.13.991307", "abstract": "<p>The outbreak of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has infected more than 100,000 people worldwide with over 3,000 deaths since December 2019. There is no cure for COVID-19 and the vaccine development is estimated to require 12-18 months. Here we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (Prophylactic Antiviral CRISPR in huMAN cells), for viral inhibition that can effectively degrade SARS-CoV-2 sequences and live influenza A virus (IAV) genome in human lung epithelial cells. We designed and screened a group of CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs for cleaving SARS-CoV-2. The approach is effective in reducing respiratory cell viral replication for H1N1 IAV. Our bioinformatic analysis showed a group of only six crRNAs can target more than 90% of all coronaviruses. The PAC-MAN approach is potentially a rapidly implementable pan-coronavirus strategy to deal with emerging pandemic strains.</p>", "twitter_description": "The outbreak of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has infected more than 100,000 people worldwide with over 3,000 deaths since December 2019. There is no cure for COVID-19 and the vaccine development is estimated to require 12-18 months. Here we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (Prophylactic Antiviral CRISPR in huMAN cells), for viral inhibition that can effectively degrade SARS-CoV-2 sequences and live influenza A virus (IAV) genome in human lung epithelial cells. We designed and screened a group of CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs for cleaving SARS-CoV-2. The approach is effective in reducing respiratory cell viral replication for H1N1 IAV. Our bioinformatic analysis showed a group of only six crRNAs can target more than 90% of all coronaviruses. The PAC-MAN approach is potentially a rapidly implementable pan-coronavirus strategy to deal with emerging pandemic strains.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.13.991307v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.13.991307v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.13.991307v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.13.991307.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.13.991307v1", "access_rights": "restricted", "authors": ["Timothy R. Abbott", "Girija Dhamdhere", "Yanxia Liu", "Xueqiu Lin", "Laine Goudy", "Leiping Zeng", "Augustine Chemparathy", "Stephen Chmura", "Nicholas S. Heaton", "Robert Debs", "Tara Pande", "Drew Endy", "Marie La Russa", "David B. Lewis", "Lei S. Qi"]}